Results 211 to 220 of about 48,363 (248)
Some of the next articles are maybe not open access.
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Current Atherosclerosis Reports, 2013The link between proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesterol metabolism was established only in 2003 when genetic mapping and positional cloning in patients with autosomal dominant hypercholesterolemia in which linkage to the loci coding for the LDL receptor and apolipoprotein B had been excluded identified the genetic defect ...
Evan A, Stein, Gary D, Swergold
openaire +2 more sources
Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention
Current Pharmaceutical Design, 2018Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events.
Ali, Ali +2 more
openaire +2 more sources
Identification of Novel cDNAs Encoding Human Kexin-Like Protease, PACE4 Isoforms
Biochemical and Biophysical Research Communications, 1994PACE4 has been identified as a second human subtilisin-like protease by Keifer et al. [DNA and Cell Biology (1991) 10, 757-769]. In this study, we isolated two novel cDNAs coding for PACE4 isoforms (PACE4C and PACE4D) from a human placenta cDNA library.
A, Tsuji +6 more
openaire +2 more sources
Proprotein convertase subtilisin/kexin type 9 related familial hypercholesterolaemia
The British Journal of Diabetes & Vascular Disease, 2012Gain-of-function proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations are an uncommon cause of familial hypercholesterolaemia (FH) with a reported frequency of less than 2% in patients with FH in the United Kingdom. We have found a high prevalence of this genotype in our patients with FH in northwest England.
Sally L Hanton, Charles Van Heyningen
openaire +1 more source
A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9
DNA and Cell Biology, 2008Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the most recently identified member of the proprotein convertase family. Genetic and cell biology studies have suggested a critical role of PCSK9 in regulating low-density lipoprotein receptor (LDLR) protein levels and thus modulating plasma LDL cholesterol. Recent data on the molecular basis for
Robert J, Schmidt +13 more
openaire +2 more sources
Proprotein convertase subtilisin/kexin type 9 in human disease
2011Cardiovascular disease (CVD) is the leading cause of death in the 21st century. Among risk factors, hypercholesterolemia and abdominal obesity are directly linked to premature development of atherosclerosis. Familial hypercholesterolemia, commonly due to low-density lipoprotein receptor (LDLR) deficiency, is known to cause premature atherosclerosis and
openaire +1 more source
Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis.
Clinical and experimental rheumatology, 2017Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked with cardiovascular risk. The purpose of the present study was to examine whether PCSK9 levels are related to both abnormalities in the lipid profile and the ...
Ivan, Ferraz-Amaro +10 more
openaire +1 more source
Hemmung der Proproteinkonvertase Subtilisin/Kexin Typ 9
Der Diabetologe, 2018Dirk Müller-Wieland +3 more
openaire +1 more source